Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dnalite Therapeutics Inc. operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The current prosecution landscape is defined by 1 pending office action, representing the current workload before the USPTO. This action is assigned to 1 distinct examiner, MITCHELL, EDWIN COLEMAN, who is the only examiner identified in the data. Additionally, the portfolio's activity is confined to a distinct art unit, which indicates a focused technical direction for the pending therapeutic claims. MITCHELL, EDWIN COLEMAN is the busiest examiner, with the busiest examiner pending action currently under review.
For patent practitioners, the presence of 1 pending office action suggests a highly concentrated prosecution strategy. Since a distinct examiner and a distinct art unit are involved, the company can focus its resources on the specific requirements and historical trends of that single examination environment. The fact that MITCHELL, EDWIN COLEMAN handles the busiest examiner pending action confirms that all current USPTO interactions are centralized. This focus within the Biotechnology & Pharmaceuticals sector allows for a precise approach to addressing office actions and technical hurdles.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MITCHELL, EDWIN COLEMAN | 1 | 32.1% | +65.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17619036 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | MITCHELL, EDWIN COLEMAN | 89d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17619036 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | MITCHELL, EDWIN COLEMAN | 89d overdue |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17619036 | COMPOSITIONS AND METHODS FOR BIOLOGICAL DELIVERY VEHICLES | MITCHELL, EDWIN COLEMAN | 1619 | §103§112 | Final Rejection | 89d overdue | Pending | Dec 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDnalite Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Edwin Coleman Mitchell has the most, with 1 of Dnalite Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
